Friday, June 02, 2023 1:39:42 PM
REPORT #21 (2023) For Week Ending 5/26/2023.
Thanks once again to @rafunrafun for providing the script data.
You can find this week’s Report (05/26/2023) here.
https://drive.google.com/file/d/1blPjrm9A0v3g6J-BvszBt7UKZoyHnPUe/view?usp=sharing
Summary: The Total Market was almost identical to last week (172,355 vs. 172948; -0.34%). Generic VASCEPA® + VASCEPA® was also unchanged vs. last week (106,707 vs. 106,910; -0.55%) See Slide #1 & #2. Individually: V -0.44%, GLV -0.59%, Hikma -4.00%, ApoTex -3.35%, DRL +2.99%, TEVA +4.27%, NorthStar moves ahead of TEVA with a +22.60%. See Slide #9. For Q2 VASCEPA® holding at 57.02% market share (Slide #5); and 56.41% for the week ending 5/26 (Slide #7).
VASCEPA® Scripts remain above 60,000 for Q2, average 61,223 (Slide #4). Finally, VASCEPA® Refills and GLV Refills are neck & neck (Slide 13).
Recent AMRN News
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
